BSE Live
Dec 27, 11:22Prev. Close
1.46
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Profit & Loss account of Abner Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Operating Revenues | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Employee Benefit Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Finance Costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation And Amortisation Expenses | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Total Expenses | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | |
| Profit/Loss From Continuing Operations | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | |
| Profit/Loss For The Period | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Diluted EPS (Rs.) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
11.03.2026
10.03.2026
09.03.2026
04.03.2026
Natco Pharma shares rise 2% on Pomalidomide capsules launch in US
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities